- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02988063
Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs
Effect of Polidocanol Endovenous Microfoam (PEM) Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in Venous Leg Ulcers (VLUs)
This study evaluates the addition of polidocanol endovenous microfoam (PEM) to compression therapy to determine effectiveness in improving the healing of venous leg ulcers (VLUs) in adults with severe venous disease of the great saphenous vein (GSV). All participants will receive treatment with Varithena and compression therapy.
The purpose of this study is to assess whether the use of PEM to correct superficial axial and varicose vein reflux is effective in improving healing of VLUs, over treatment with compression alone.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Compression therapy and polidocanol endovenous microfoam (PEM) are both used for the treatment of venous leg ulcers (VLUs), but they do so by different mechanisms.
Compression therapy applied by a wound care professional has been demonstrated to improve healing rates in patients with existing VLUs and to reduce ulcer recurrence, and is used consistently by treating physicians. Compression therapy consists of hosiery, tubular bandages and bandage systems comprising two or more components, which provide graduated compression to the lower limb in order to improve venous return and to reduce edema.
Polidocanol endovenous microfoam (PEM) is an injectable foam medication that is used to treat symptoms of venous disease, including venous leg ulcers (VLUs). The medication ("polidocanol") is in the foam ("endovenous microfoam"). PEM is injected through a catheter or by direct injection into the malfunctioning vein. The foam fills and treats the desired section of the vein, thereby collapsing the diseased vein. When the malfunctioning vein collapses, the microfoam is deactivated and blood flow shifts to healthier veins nearby.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- OhioHealth Riverside Methodist Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Active VLU with a CEAP classification of C6
- Non-healing VLU ≥ 1 month but not greater than 24 months
- In the case of more than one ulcer, the largest ulcer (compliant with study criteria) will be chosen as the study ulcer and treated in the study. Other ulcerations, if present on the same leg must be at least 2cm apart from the study ulcer.
- Demonstrable GSV insufficiency (as per the Society for Vascular Surgery [SVS] and the American Venous Forum [AVF] Guidelines) via venous insufficiency study (VIS) (11)
- VLU considered non-healing (clinically defined as ≤70% wound improvement) after a 4-5 week run-in period with compression therapy
- Venous leg ulcer size ≥ 2cm2 within the great saphenous distribution and must be visualized in one plane to allow for image collection of the entire wound in one photo by the Silhouette device.
- The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone
- The ulcer must be located below the knee
- The ulcer bed must have some viable tissues with some granulation tissue
- Able to tolerate effective compression bandaging
- Patients able to walk independently with or without mobility aids
- Ability to comprehend and sign an informed consent document and complete study questionnaires in English
- Able and willing to attend all follow up visits
Exclusion Criteria:
- Age < 18 years old
- Small saphenous vein (SSV) distribution VLUs
- Patients who had previously received interventions for underlying venous disease or prior VLU treatments that would not be considered to be conservative, in the opinion of the principal investigator
- Exposed bone, tendon, or fascia
- Deep vein reflux unless clinically insignificant in comparison to superficial reflux
- Patients with leg ulceration etiology other than venous insufficiency
- Severe rheumatoid arthritis
- History of radiotherapy to the ulcer site
- Uncontrolled congestive heart failure (left or right sided heart failure)
- Receiving corticosteroids or immune suppressive therapy
- Active clinical infection of the ulcer site, however, patients may be entered into the study after successful treatment of infection
- History of collagen vascular disease
- History of known malnutrition (albumin <3.0 g/dL)
- History of known uncontrolled diabetes [hemoglobin A1c (HgbA1c) >8.0%]
- History of known arterial insufficiency [ankle-brachial index (ABI) <0.7, transcutaneous oxygen (tcpO2) <35 mmHg, or toe-brachial index (TBI) <0.4]
- Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s)
- Active sickle cell disease
- Patients diagnosed with DVT or phlebitis in the affected limb in the last 6 months, or with acute pulmonary embolism (PE) in the last 6 months (contraindication to PEM)
- Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions (contraindication to PEM)
- Chronic renal disease, if deemed by the principal investigator to be severe enough to interfere with wound healing
- Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy
- Poorly controlled asthma
- Pulmonary edema
- Major surgery, prolonged hospitalization, or pregnancy within 3 months of screening
- Minor surgery within 1 month of screening
- Current alcohol or drug (illicit or prescription) abuse
- Pregnant or lactating women
- History of stroke
- Unable to comply with the procedures described in the protocol
- Unable to comply with compression therapy recommendations
- Unable to give informed consent
- Non-English speaking
- Enrolled in a clinical evaluation for another investigational wound-care device or drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Compression plus PEM
Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy.
If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
|
Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee.
PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ulcer healing rate
Time Frame: 12 weeks
|
We will determine the change in ulcer healing rate following PEM treatment.
Ulcer healing rate will be measured as the relative weekly change in ulcer perimeter (cm) from baseline, until either until fully healed, or up to the final active study visit at 12 weeks (whichever is sooner).
Pre-treatment healing rate will be measured as the relative change in ulcer perimeter (cm) from baseline per week over the 4-5 week run-in period.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who successfully heal
Time Frame: 12 weeks
|
We will determine the proportion of patients who successfully heal by 12 weeks.
"Successful" healing will be defined as complete resolution of the ulcer (0 cm), with a lack of disruption of the epithelium at the ulcer site.
|
12 weeks
|
Proportion of patients who experience symptomatic pulmonary embolism and deep vein thrombosis (PE and DVT, respectively) and other drug-related adverse events (AEs)
Time Frame: 12 weeks
|
We will determine the proportion of patients who experience symptomatic pulmonary embolism and deep vein thrombosis (PE and DVT, respectively) and other drug-related adverse events (AEs) at 12 weeks (or the last active study visit if healed prior to 12 weeks).
The most commonly reported drug-related AEs (occurring in ≥3% of patients) include pain/discomfort in extremity, infusion site thrombosis (retained coagulum), injection site hematoma or pain, and superficial thrombophlebitis.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Raghu Kolluri, MD, OhioHealth
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Gastrointestinal Diseases
- Skin Ulcer
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Ulcer
- Gastroesophageal Reflux
- Leg Ulcer
- Varicose Ulcer
- Varicose Veins
- Pharmaceutical Solutions
- Sclerosing Solutions
- Polidocanol
Other Study ID Numbers
- OH1-16-00664
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leg Ulcer
-
Nantes University HospitalCompletedHypertensive Leg UlcerFrance
-
University Hospital, Strasbourg, FranceTerminated
-
Assistance Publique - Hôpitaux de ParisCompletedMARTORELL'S ULCER | Hypertensive Leg Ulcer | Necrotic AngiodermatitisFrance
-
Pharma 2100WithdrawnArterial Leg UlcerDenmark
-
SoftOx Solutions ASCompletedVenous Leg Ulcer | Chronic Leg UlcerDenmark
-
Piomic Medical AGVenenklinik Bellevue; Kantonsspital Nidwalden; Spital MännedorfCompletedLeg Ulcers Venous | Leg Ulcer Arterial | Leg Ulcer MixedSwitzerland
-
Ahram Canadian UniversityRecruiting
-
Central Hospital, Nancy, FranceUnknownArteritic Leg Ulcer
-
SolasCure LimitedCompletedVenous Leg Ulcer | Leg Injuries and DisordersUnited States, Hungary, United Kingdom
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
Clinical Trials on Polidocanol Endovenous Microfoam (PEM)
-
Boston Scientific CorporationBTG International Inc.Completed
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationCompletedGreat Saphenous Vein Incompetence | Visible VaricositiesUnited States
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationCompleted
-
Imperial College LondonTerminated
-
ProMedica Health SystemJobst Vascular InstituteRecruitingVenous Insufficiency | Venous Reflux | Venous Ulcer | Venous DiseaseUnited States
-
Societe Francaise de PhlebologieCompletedVaricose Veins of Lower Limb